Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$1.69 - $4.37 $338 - $874
-200 Reduced 16.67%
1,000 $4,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $5,340 - $9,743
1,200 New
1,200 $5,000

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $125M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.